Addex Therapeutics reported a significant decrease in sales for Q2, down 71.27% year-over-year, alongside a reduction in per-share losses. The substantial drop in revenue indicates potential operational challenges or a decline in product demand, which is a major concern for investors.
Addex Therapeutics (ADXN) disclosed its Q2 earnings, revealing a dramatic 71.27% year-over-year decrease in sales, falling from $44.031 thousand to $12.650 thousand. While the company did narrow its per-share losses from $(2.90) to $(2.16), the substantial revenue decline is the dominant factor. This indicates a significant operational setback or reduced market penetration, which will likely lead to negative investor sentiment and pressure on the stock price in the short term. For traders, this presents a clear bearish signal, as the company's ability to generate revenue is severely impacted, raising questions about its long-term financial viability and growth prospects.